Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label comparison of Kamada anti-SARS-CoV-2 IgG versus high-titer convalescent plasma in hospitalized patients with moderate to severe COVID-19
MOH_2021-01-14_009667Phase 2Recruiting
- Sponsor
- יסמין מאור
- Start
- Jan 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anti-SARS-CoV-2 IgG in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by יסמין מאור. Started Jan 2021; status: recruiting.
02
Drugs
anti-SARS-CoV-2 IgG
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on MOH_2021-01-14_009667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-14_009667.